1st quarter 2006 :Strong sales growth of 17%

(1) Germany, Italy, Spain/Portugal, Belgium
(2) + 9% organic growth

• Sales in the first quarter again grew significantly in all markets.

• Growth in France of 17% and in the subsidiaries (9% organic) is based on strong growth in initial treatments.

• Stallergènes continues to increase its market share due to an enlarged innovative commercial service offering and continuous growth in desensitisation by the sublingual route.  This also benefited from the positive impact of the clinical study ORALAIR® Grasses communicated at the end of 2005.

• Sales to distributors again started to grow (up 18%).

This good start to the year supports the target of growth close to 10% for 2006.